Deubiquitylating enzymes: multiple drug opportunities in oncology and across therapeutic areas
Robust and proprietary enabling
Yielding novel therapeutics for the
benefit of patients
MISSION Therapeutics is a private, drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat diseases of high unmet need.
We have built a World-leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’.
MISSION Therapeutics’ DUB platform has enabled the development of a pipeline of DUB programmes that have been selected for their potential to address unmet needs in major disease areas with high commercial potential.